Our writers · the desk
Two writers. One bill.
Two beats, split the way a purchase splits: pricing analyst and consumer-access reporter. Each writer owns one of them, and the same name always covers the same ground, so you know whose reasoning to argue with.
- Byline 01Pricing analyst
Derek Moss
Reads the bill, not the banner, and prints the figure you will actually pay each month.
Beat — What each seller actually bills per month: the fees outside the headline, the prepay terms, and the figure a reader will pay.
All-in monthly pricingMembership and consult feesPrepay and subscription termsPer-vial and per-dose price conversionPromotional versus standing prices
Published here
- Research answers
- 30
- Guides
- 2
- Seller reviews
- 8
- Total
- 40
Latest
- ResearchGLP-1 Cost Without Insurance: Every Maker's Self-Pay PriceSeptember 2026
- ResearchHow Long Does a Vial of Tirzepatide Last? Four Doses, Then DiscardSeptember 2026
- ResearchLiraglutide Cost: Saxenda's List Price, Generics and Pens per MonthSeptember 2026
- ResearchMounjaro Cost: The Self-Pay Price, the Savings Card and ZepboundSeptember 2026
- Byline 02Consumer-access reporter
Jenna Pratt
Reports how prescribing, pharmacies and cancellation actually work, so the price you see is the process you get.
Beat — How to actually get a peptide prescribed: the telehealth visit, the pharmacy, state availability, cancellation and what each step costs.
Telehealth intake and prescribingCompounding pharmacy rulesState availabilityCancellation and refund termsInsurance and cash-pay access
Published here
- Research answers
- 32
- Guides
- 1
- Seller reviews
- 4
- Total
- 37
Latest
- ResearchIs Wegovy Covered by Insurance? Employer Plans, Medicaid and the FallbackSeptember 2026
- ResearchPT-141 Nasal Spray: What the Compounded Spray Costs and What Is KnownSeptember 2026
- Research503A vs 503B: The Two Kinds of Compounding Pharmacy, ComparedSeptember 2026
- ResearchAre Peptides Legal? What You Can Get Prescribed, and WhySeptember 2026
What a byline here does not claim
Nobody on this desk holds a medical, pharmacy or law license, and no byline pretends to. A made-up title is a cheap way to sell a peptide, so we check receipts instead: each price shows the month it was read, and each dose or rule links to the label, trial or regulator’s page it came from. Hold us to those links.
The methodology explains how a price reaches a board; the editorial policy sets out what we will not claim.